PCI BIOTECH HOLDING ASA

PCI Biotech Holding is a biopharmaceutical company focusing on the development and commercialization of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform. PCI is applied to three distinct anticancer paradigms: fimaCHEM (enhancement of chemotherapeutic for localized treatment of cancer), fimaVACC (T-cell induction technology for therapeutic vaccination), and fimaNAc (nucleic acid therapeutic delivery). Photochemical internal... isation induces triggered endosomal release that is used to unlock the true potential of a wide array of therapeutic modalities. The company’s lead fimaCHEM program consists of a clinical Phase I/II clinical study in bile duct cancer, an orphan indication with a high unmet need and without approved products. FimaVACC applies a unique mode of action to enhance the essential cytotoxic effect of therapeutic cancer vaccines, which works in synergy with several other state-of-the-art vaccination technologies. Finance utilizes the endosomal release to provide intracellular delivery of nucleic acids, such as MRNA and siRNA therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising Field.More